The clinical significance of extended spectrum beta-lactamases;El significado clínico de las betalactamasas de espectro extendido

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 21, Issue 2, 2003, Pages 69-71

  Pujol, Miquel ^a   Peña, Carmen ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFOTAXIME; CEFPODOXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; MONOBACTAM DERIVATIVE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN;

CLINICAL MEDICINE; EDITORIAL; ENZYME STRUCTURE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR BIOLOGY; NONHUMAN; PROTEUS; SALMONELLA; SERRATIA; SPAIN;

EID: 17044460342     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13042861     Document Type: Editorial

References (20)

1. Hernández JR, Pascual A, Cantón R, Martínez-Martínez L y Grupo de Estudio Infección Hospitalaria (GEIH). Escherichia coli y Klebsiella pneumoniae productores de betalactamasas de espectro extendido en hospitales españoles (Proyecto GEIH-BLEE 2000). Enferm Infecc Microbiol Clin 2003; 21:77-82.
2. Bermejo J, Lesnaberes P, Arnesi N, Gianello M, Notario R, Borda N, et al. Factores de riesgo asociados con las infecciones debidas a Klebsiella pneumoniae resistentes a ceftacidima. Enferm Infecc Microbiol Clin 2003;21:72-6.
3. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995;39:1211-33.
4. Winokur PL, Cantón R, Casellas JM, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific Region. Clin Infect Dis 2001:32(Suppl 2):S94-103.
5. Yuan M, Aucken H, Hall LMC, Pitt TL, Livermore DM. Epidemiological typing of klebsiellae with extended-spectrum β-lactamases from European intensive care units. J Antimicrob Chemother 1998;41:527-39.
6. Peña C, Pujol M, Ardanuy C, Ricard A, Pallarés R, Liñares J, et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum β-lactamases. Antimicrob Agents Chemother 1998;42:53-8.
7. Wiener J, Quinn JP, Bradford PA, Goering RV, Nathan C, Bush K, et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999;281:517-23.
8. Gniadkouwski M. Evolution and epidemiology of extended-spectrum β-lactamases (ESBLs) and ESBL-producing microorganisms. Clin Microbiol Infect 2001;7:597-608.
9. Paterson DL, Ko WC, Von Gottberg A, Casellas JM, Mulazimoglu L, Klugman KP, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: Implications for the clinical microbiology laboratory. J Clin Microbiol 2001;39:2206-12.
10. Wong-Beringer A, Hindler J, Loeloff M, Weenan AM, Lee N, Pegues DA, et al. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin Infect Dis 2002;34:135-46.
11. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. 12th informational supplement ed. Wayne: National Committee for Clinical Laboratory Standards, 2002.
12. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infections resistant to late-generation cephalosporins. Ann Intern Med 1993;119:353-8.
13. Asensio A, Oliver A, González-Diego P, Baquero F, Pérez-Díaz JC, Ros P, et al. Outbreak of a multiresistant Klebsiella pneumoniae strain in an intensive care unit: Antibiotic use as a risk factor for colonization and infection. Clin Infect Dis 2000;30:55-60.
14. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: Risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001;32:1162-71.
15. Kim YK, Pai H, Lee HJ, Park SE, Choi EH, Kim J, et al. Bloodstream infections by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: Epidemiology and clinical outcome. Antimicrob Agents Chemother 2002;46:1481-91.
16. Peña C, Pujol M, Ardanuy C, Ricart A, Pallarés R, Liñares J, et al. An outbreak of hospital-acquired Klebsiella pneumoniae bacteremia, including strains producing extended-spectrum β-lactamase. J Hosp Infect 2001;47: 53-9.
17. Spanu T, Luzzaro F, Perilli M, Amicosante G, Toniolo A, Fadda G, and The Italian ESBL Study Group. Occurrence of extended-spectrum β-lactamases in members of the family enterobacteriaceae in Italy: implications for resistance to β-lactams and other antimicrobial drugs. Antimicrob Agents Chemother 2002;46:196-202.
18. Johnson DM, Biedenbach DJ, Jones RN. Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): Emphasis on its activity against resistant organisms populations and generally untested species causing community-acquired respiratory tract infections. Diagn Microbiol Infect Dis 2002;43:49-60.
19. Paterson DL, Mulazimoglu, Casellas JM, Ko WC, Goossens H, Gottberg AV, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000;30:473-8.
20. Ahmad M, Urban C, Mariano N, Bradford PA, Calcagni E, Projan SJ, et al. Clinical characteristics and molecular epidemiology associated with imipenem-resistant Klebsiella pneumoniae. Clin Infect Dis 1999;29:352-5.